CO2022019251A2 - Composiciones y métodos útiles para la prevención y/o el tratamiento de enfermedades en mamíferos - Google Patents
Composiciones y métodos útiles para la prevención y/o el tratamiento de enfermedades en mamíferosInfo
- Publication number
- CO2022019251A2 CO2022019251A2 CONC2022/0019251A CO2022019251A CO2022019251A2 CO 2022019251 A2 CO2022019251 A2 CO 2022019251A2 CO 2022019251 A CO2022019251 A CO 2022019251A CO 2022019251 A2 CO2022019251 A2 CO 2022019251A2
- Authority
- CO
- Colombia
- Prior art keywords
- kda
- ksp37
- subject
- diseases
- proteins
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 241000124008 Mammalia Species 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 102100023589 Fibroblast growth factor-binding protein 2 Human genes 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 101710094941 Fibroblast growth factor-binding protein 2 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001132—Fibroblast growth factors [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Marine Sciences & Fisheries (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA202003850 | 2020-07-09 | ||
| ZA202004008 | 2020-07-09 | ||
| PCT/IB2021/056179 WO2022009165A1 (en) | 2020-07-09 | 2021-07-09 | Compositions and methods useful for the prevention and/or treatment of disease in mammals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022019251A2 true CO2022019251A2 (es) | 2023-03-27 |
Family
ID=79552952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0019251A CO2022019251A2 (es) | 2020-07-09 | 2022-12-29 | Composiciones y métodos útiles para la prevención y/o el tratamiento de enfermedades en mamíferos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240091310A1 (https=) |
| EP (1) | EP4178604A4 (https=) |
| JP (1) | JP2023533162A (https=) |
| KR (1) | KR20230038230A (https=) |
| CN (1) | CN115720520A (https=) |
| AU (1) | AU2021304479A1 (https=) |
| BR (1) | BR112022026874A2 (https=) |
| CA (1) | CA3179965A1 (https=) |
| CL (1) | CL2023000073A1 (https=) |
| CO (1) | CO2022019251A2 (https=) |
| IL (1) | IL299661A (https=) |
| MX (1) | MX2023000113A (https=) |
| PE (1) | PE20231554A1 (https=) |
| PH (1) | PH12023550038A1 (https=) |
| WO (1) | WO2022009165A1 (https=) |
| ZA (1) | ZA202213371B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025215561A1 (en) * | 2024-04-09 | 2025-10-16 | Viro-Gen (Pty) Ltd | Plasmid for expression of ksp37 |
| WO2025221871A1 (en) * | 2024-04-16 | 2025-10-23 | The Trustees Of Columbia University In The City Of New York | Expansion, propagation, and modulation of immune cell subsets by peptides |
| WO2025233868A1 (en) * | 2024-05-07 | 2025-11-13 | Viro-Gen (Pty) Ltd | Compounds, compositions and methods for treating, reversing or preventing cancer |
| WO2025233869A1 (en) * | 2024-05-07 | 2025-11-13 | Viro-Gen (Pty) Ltd | Compounds, compositions and methods for treating, reversing or preventing type 2 diabetes mellitus |
-
2021
- 2021-07-09 BR BR112022026874A patent/BR112022026874A2/pt unknown
- 2021-07-09 US US18/004,631 patent/US20240091310A1/en active Pending
- 2021-07-09 AU AU2021304479A patent/AU2021304479A1/en active Pending
- 2021-07-09 CN CN202180042656.8A patent/CN115720520A/zh active Pending
- 2021-07-09 PE PE2022003070A patent/PE20231554A1/es unknown
- 2021-07-09 MX MX2023000113A patent/MX2023000113A/es unknown
- 2021-07-09 CA CA3179965A patent/CA3179965A1/en active Pending
- 2021-07-09 WO PCT/IB2021/056179 patent/WO2022009165A1/en not_active Ceased
- 2021-07-09 PH PH1/2023/550038A patent/PH12023550038A1/en unknown
- 2021-07-09 JP JP2022575231A patent/JP2023533162A/ja active Pending
- 2021-07-09 EP EP21838245.5A patent/EP4178604A4/en active Pending
- 2021-07-09 KR KR1020237004448A patent/KR20230038230A/ko active Pending
- 2021-07-09 IL IL299661A patent/IL299661A/en unknown
-
2022
- 2022-12-09 ZA ZA2022/13371A patent/ZA202213371B/en unknown
- 2022-12-29 CO CONC2022/0019251A patent/CO2022019251A2/es unknown
-
2023
- 2023-01-06 CL CL2023000073A patent/CL2023000073A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023533162A (ja) | 2023-08-02 |
| EP4178604A4 (en) | 2024-07-31 |
| PH12023550038A1 (en) | 2024-03-11 |
| KR20230038230A (ko) | 2023-03-17 |
| WO2022009165A1 (en) | 2022-01-13 |
| IL299661A (en) | 2023-03-01 |
| BR112022026874A2 (pt) | 2023-01-24 |
| CA3179965A1 (en) | 2022-01-13 |
| AU2021304479A1 (en) | 2023-01-19 |
| PE20231554A1 (es) | 2023-10-03 |
| MX2023000113A (es) | 2023-03-16 |
| EP4178604A1 (en) | 2023-05-17 |
| ZA202213371B (en) | 2023-11-29 |
| CN115720520A (zh) | 2023-02-28 |
| US20240091310A1 (en) | 2024-03-21 |
| CL2023000073A1 (es) | 2023-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022019251A2 (es) | Composiciones y métodos útiles para la prevención y/o el tratamiento de enfermedades en mamíferos | |
| CY1119295T1 (el) | Γονιδιακη θεραπεια για ασθενειες λυσοσωμικης αποθhκευσης | |
| Traboulsi et al. | The flavonoid isoliquiritigenin reduces lung inflammation and mouse morbidity during influenza virus infection | |
| CO2022002638A2 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen una mutación en el gen gla | |
| Subramaniam et al. | Delivery of GM-CSF to protect against influenza pneumonia | |
| EP4289476A3 (en) | Methods of treating fabry disease in patients having a mutation in the gla gene | |
| JP2018516944A5 (https=) | ||
| JOP20220259A1 (ar) | تركيبات تشتمل على جسيمات نانونية، طريقة تصنيعها واستخدامها | |
| BR112022009798A2 (pt) | Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer | |
| MX2012004409A (es) | Proteina recombinante de humano cc10 para el tratamiento de la influenza. | |
| US20190064180A1 (en) | Diagnosis of immune_activation using clever-1, tnf-alpha and hla-dr binding agents | |
| MX2022012165A (es) | Interaccion de proteinas de sars-cov-2 con mecanismos moleculares y celulares de celulas huespedes y formulaciones para tratar covid-19. | |
| EP3107558B1 (en) | Treating infection | |
| EP4233912A3 (en) | Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients | |
| EP2903634A1 (en) | Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza | |
| KR20230027279A (ko) | 화학요법-유발성 독성을 완화하기 위한 내피 세포 | |
| JOP20240243A1 (ar) | أجسام مضادة لـ angptl3 جديدة مناسبة لتركيبات عالية التركيز والإعطاء تحت الجلد | |
| ZA202401042B (en) | Protein compositions for the treatment of inflammatory diseases | |
| BR112023020732A2 (pt) | Vetor lentiviral para o tratamento da hepatite b, método e preparação de partículas lentivirais para o tratamento da mesma e composição farmacêutica para o tratamento e/ou prevenção da infecção pelo vírus da hepatite b | |
| MX2022004060A (es) | El uso del agente para inducir inmunidad especifica contra virus de sindrome respiratorio agudo severo sars-cov-2 en sujetos mayores de 60 a?os y/o que tienen enfermedades cronicas (variantes). | |
| AR124744A1 (es) | AGENTE PARA USO EN LA INDUCCIÓN DE INMUNIDAD ESPECÍFICA CONTRA EL VIRUS DEL SÍNDROME RESPIRATORIO SEVERO AGUDO SARS-CoV-2 EN SUJETOS MAYORES DE 60 AÑOS DE EDAD Y/O QUE TIENEN ENFERMEDADES CRÓNICAS (VARIANTES) | |
| JP2014531442A5 (https=) | ||
| Pourjabbar et al. | Cell therapy based SARS-cov 2-2019 managements: A literature review | |
| CL2018002378A1 (es) | Medicamento útil como sustituto sanguineo para tratar, a la vez, la anemia aguda por pedida de sangre y la infección bacteriana en mamíferos | |
| MA58651A1 (fr) | Compositions et procédés utiles pour la prévention et/ou le traitement de maladie chez des mammifères |